IASLC World Conference on Lung Cancer | Conference

Dr. Ramalingam on the Role of Osimertinib in EGFR T790M-Positive Advanced NSCLC

December 7th 2016

Suresh S. Ramalingam, MD, professor, Department of Hematology and Medical Oncology, Deputy Director, Winship Cancer Institute of Emory University, discusses the role of osimertinib in the treatment of patients with EGFR T790M-positive advanced non-small cell lung cancer, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Osimertinib Beats Chemo in Second-Line T790M-Mutant NSCLC

December 7th 2016

Osimertinib (Tagrisso) reduced the risk of disease progression by 70% compared with a chemotherapy doublet in patients with EGFR T790M-mutant non–small cell lung cancer (NSCLC) who progressed after first-line targeted therapy.

Frontline Ceritinib Improves PFS Over Platinum-Based Chemo in ALK+ NSCLC

December 7th 2016

Frontline treatment with ceritinib (Zykadia) improved progression-free survival over standard chemotherapy in patients with ALK-rearranged non–small cell lung cancer.

Dr. Juergens on the IND.226 Trial in Advanced Non-Squamous NSCLC

December 6th 2016

Rosalyn Juergens, MD, PhD, assistant professor, Department of Oncology, Division of Medical Oncology, McMaster University, discusses the results of the IND.226 trial, in an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Dr. Verschraegen on the JAVELIN Solid Tumor Trial in Advanced NSCLC

December 6th 2016

Claire Verschraegen, MD, professor of Medical Oncology, University of Vermont Cancer Center, discusses the results of the JAVELIN Solid Tumor trial during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Icotinib Improves Intracranial PFS in EGFR-Mutant NSCLC and Brain Mets

December 6th 2016

Treatment with icotinib more than doubled intracranial progression-free survival compared with whole brain irradiation combined with standard chemotherapy.

Improved PFS, ORR With Frontline Nivolumab and Nivolumab/Ipilimumab Combo in NSCLC

December 6th 2016

Findings from an efficacy update of patients participating in a study in the CheckMate series revealed that first-line nivolumab (Opdivo) demonstrated activity in advanced non–small cell lung cancer, and the addition of ipilimumab (Yervoy) resulted in enhanced activity, specifically in prolonged progression-free survival and higher objective response rates.

Early Results Positive for First-Line Avelumab in NSCLC

December 6th 2016

Treatment with first-line avelumab yielded promising clinical benefit and durable antitumor activity in patients with advanced non–small cell lung cancer.

Dr. Roth on the Rationale Behind a Novel Risk-Prediction Model in Lung Cancer Screening

December 5th 2016

Joshua Roth, PhD, assistant member, Fred Hutchinson Cancer Research Center, discusses the rationale behind the development of a novel risk-prediction algorithm in the context of screening patients for lung cancer. He discussed this during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Dr. Zulueta on the Non-Invasive LuCED Test for Detection of Early Stage Lung Cancer

December 5th 2016

Javier Zulueta, MD, head of the Pneumology Department, co-director, Lung Cancer Area, Clinica Universidad de Navarra, discusses the LuCED test, a non-invasive tool used to detect early stage lung cancer, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Prognostic Factors Plus PD-L1 Expression May Be Linked With Early Survival Risk for Nivolumab in NSCLC

December 5th 2016

While treatment with nivolumab (Opdivo) significantly improved overall survival over docetaxel in patients with advanced non–small cell lung cancer in the CheckMate-057 trial, an analysis of deaths occurring within 3 months of initiation of therapy showed numerically more deaths in the nivolumab arm.

Expert Highlights Importance of Novel Findings With Tobacco Cessation Practices

December 5th 2016

Douglas Arenberg, MD, discusses preliminary findings of a screening study, and the critical importance of maintaining quality tobacco cessation practices in healthcare clinics.